Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

been added to

diluted weighted average shares outstanding for both of these periods

for purposes of computing diluted earnings per share.

GENZYME CORPORATION (GENZ)

Condensed Consolidated Balance Sheets March 31, December 31,

(Unaudited, amounts in thousands) 2008 2007

Cash and all marketable securities $1,447,983 $1,460,394

Other current assets 1,818,541 1,661,740

Property, plant and equipment, net 2,118,960 1,968,402

Intangibles, net (1) 3,386,451 2,959,480

Other assets (2) 311,581 251,725

Total assets $9,083,516 $8,301,741

Current liabilities $1,475,663 $1,502,406

Noncurrent liabilities (1) 658,936 186,398

Stockholders' equity 6,948,917 6,612,937

Total liabilities and stockholders'

equity $9,083,516 $8,301,741

(1) Effective January 1, 2008, in connection with the restructuring of

BioMarin/Genzyme LLC, our joint venture with BioMarin Pharmaceutical

Inc., we licensed certain rights to commercialize Aldurazyme from the

joint venture and, in accordance with the provisions of FASB

Interpretation No. 46R, "Consolidation of Variable Interest Entities,"

began consolidating the results of the joint venture at fair value. As

of March 31, 2008, intangibles, net, includes $480,500K for the fair

value of the joint venture's manufacturing and commercialization

rights to Aldurazyme, offset by $(6,006)K of related accumulated

amortization. Noncurrent liabilities includes $474,494K of additional

net liabilities relat
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
(Date:7/24/2014)... to materialise. Yet, scientists are making progress in ... One such approach relies on quantum dotsa kind ... electric field. A new study demonstrates that changing ... (TQDs) with electrical impulses can help better control ... be used as quantum information units, which would ...
(Date:7/24/2014)... Research and Markets has announced ... Analytical Instruments Market 2014-2018" report to their offering. ... Genomics is the study of the gene and its ... and functions of proteomes or sets of proteins by ... involves the mapping of genes and DNA sequencing to ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2
... Calif., March 30 Oxygen Biotherapeutics, Inc. (OTC Bulletin ... shareholders, prospective investors and interested parties in Zurich, Switzerland ... will be to update the investment community on the ... be available to answer shareholder questions along with ...
... Amicus Therapeutics (Nasdaq: FOLD ) today announced ... be presenting at the upcoming 16th ... at New York City,s Millennium Broadway Hotel and Conference Center. ... April 2, 2009 at 9:30 a.m. EDT.Individuals can listen to ...
... Graeme Clark Scholarship WinnersDENVER, March 30 Cochlear ... today announced the winners of the 2009 Graeme ... Cochlear Scholarship Foundation has recognized the remarkable achievements ... implant - a small electronic device that can ...
Cached Biology Technology:Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland 2Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education 2Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education 3Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education 4Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education 5
(Date:7/24/2014)... sobering examples of how wildlife loss leads to conflict ... by Wildlife Conservation Society (WCS) Health & Ecosystems: ... calls for an interdisciplinary approach to tackle global biodiversity ... about 15% of the world,s people and provides protein ... It should come as no surprise that today,s unprecedented ...
(Date:7/24/2014)... 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, an innovative ... cut emergency room wait times by an average of ... Center, according to a recent study published in the ... using the suite to access data from incoming patients, ... "Using Geneva,s technology platform we have been able ...
(Date:7/24/2014)... food or commercial food sale, has been heavily documented ... many species of primates and other mammals. However, ... the species being consumed are birds, particularly large birds ... meat made available for sale but the meat that ... brought to villages for consumption, we noted a significant ...
Breaking Biology News(10 mins):New study draws links between wildlife loss and social conflicts 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... planetary scientists at Washington University in St. Louis are studying ... years ago. , While that might sound a bit like ... winter, the snails actually reveal clues about the climate and ... also could shed light on the possible role weather and ...
... recent Genomed-Health 2005 workshop in Tunisia, supported by ... life sciences in improving health in countries bordering ... discussed the importance of Euro-Mediterranean partnerships in order ... sciences ?in particular following the mapping of the ...
... News) and Karolinska Institutet announced today that they ... improve healthcare by accelerating the translation of basic ... and treatment. , During the next five years ... gene expression in patients with atherosclerosis, breast cancer, ...
Cached Biology News:Scientists find fossil proof of Egypt's ancient climate 2Scientists find fossil proof of Egypt's ancient climate 3Measuring the impact of post-genomics on Mediterranean populations 2Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 2Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 3
The piston kit includes 2 pistons to service one F10 pump of a BioLogic DuoFlow workstation....
BD BioCoat BD MatrigelTM Matrix 100 mm Culture Dishes for hepatocytes, tissue-culture treated polystyrene with a uniform application of MATRIGEL Matrix....
The F40 piston assembly is supplied as two assemblies to service one F40 pump of a BioLogic DuoFlow workstation....
...
Biology Products: